|
|
Patient Instructions & Colonoscopy Prep Video
This information is intended for U.S. residents only.
A colonoscopy is a routine, generally safe, pain–free procedure used to examine the colon. To ensure the effectiveness and safety of the procedure,
there are several steps that you must take during your colonoscopy prep with MoviPrep.
- Make arrangements to have someone drive you home after the procedure
- Colonoscopy involves sedation, and you will not be allowed
to leave by yourself
- Follow your doctor's instructions regarding medicines to avoid and diet to follow before your procedure
- Finish the entire bowel prep regimen
- Make a conscious effort to drink as much clear liquid as possible before, during, and after the colon prep
To view MoviPrep's simple dosing and easy to follow animated video, please click the Play button below:
Two Flexible Dosing Methods
Unlike other PEG bowel preparations, MoviPrep can be taken as an evening–before dose or a split dose.
For the evening–before regimen, all of the MoviPrep bowel prep solution is taken the night before the colonoscopy procedure. For the split–dose
regimen, the MoviPrep bowel prep solution is divided equally between the night before the colonoscopy and the morning of the procedure.
Regardless of which bowel preparation dosing method you and your doctor choose, it is important to follow your doctor's instructions regarding MoviPrep
or any other prescription medications.
Please download full Patient Instructions by clicking on the link below.
Get Adobe Acrobat Reader
MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. MOVIPREP is contraindicated in patients with gastrointestinal (GI) obstruction, bowel perforation, gastric retention, ileus, toxic colitis or toxic megacolon, and patients who have had a severe hypersensitivity reaction to any of its components. MOVIPREP should be used with caution in patients at risk of or with fluid and electrolyte abnormalities, hyponatremia, arrhythmias, seizures, in patients with impaired renal function or patients taking concomitant medications that affect renal function, patients with known or suspected inflammatory bowel disease, patients with suspected GI obstruction or perforation, patients at risk for aspiration, and patients with glucose-6-phosphate dehydrogenase deficiency. Most common adverse reactions for split dosing (incidence ≥ 5%) are malaise, nausea, abdominal pain, vomiting, and upper abdominal pain. The most common adverse reactions for evening only dosing (incidence ≥ 5%) are abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness. MOVIPREP contains 2.33 mg of phenylalanine per treatment. Advise patients to hydrate adequately before, during, and after the use of MOVIPREP.
For complete Prescribing Information, please click here.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email:
|
|